These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36565735)

  • 21. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.
    Bachireddy P; Rakhra K; Felsher DW
    Clin Exp Immunol; 2012 Feb; 167(2):188-94. PubMed ID: 22235994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
    Felsher DW
    Cancer Res; 2008 May; 68(9):3081-6; discussion 3086. PubMed ID: 18451131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
    Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The trk family of oncogenes and neurotrophin receptors.
    Lamballe F; Klein R; Barbacid M
    Princess Takamatsu Symp; 1991; 22():153-70. PubMed ID: 1844238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Causal role for an activated N-ras oncogene in the induction of tumorigenicity acquired by a human cell line.
    Tainsky MA; Shamanski F; Blair D; Giovanella BC
    Cancer Res; 1987 Jun; 47(12):3235-8. PubMed ID: 3034405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenes in chronic lymphocytic leukemia.
    Butturini A; Gale RP
    Leuk Res; 1988; 12(1):89-92. PubMed ID: 3282128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.
    Gavralidis A; Gainor JF
    Cancer J; 2020; 26(6):517-524. PubMed ID: 33298723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The v-erbA oncogene requires cooperation with tyrosine kinases to arrest erythroid differentiation induced by ligand-activated endogenous c-erbA and retinoic acid receptor.
    Schroeder C; Gibson L; Beug H
    Oncogene; 1992 Feb; 7(2):203-16. PubMed ID: 1347913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The nuclear oncogenes v-erbA and v-ets cooperate in the induction of avian erythroleukemia.
    Metz T; Graf T
    Oncogene; 1992 Mar; 7(3):597-605. PubMed ID: 1347919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid induction of an experimental metastatic phenotype in first passage rat embryo cells by cotransfection of EJ c-Ha-ras and c-myc oncogenes.
    Storer RD; Allen HL; Kraynak AR; Bradley MO
    Oncogene; 1988 Feb; 2(2):141-7. PubMed ID: 3285293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor origin, progression, immunogenicity, and immunotherapy.
    Weiss DW
    Transplant Proc; 1984 Apr; 16(2):528-33. PubMed ID: 6719554
    [No Abstract]   [Full Text] [Related]  

  • 32. Oncogenes, growth factors, and autoimmune diseases (review).
    Sibbitt WL
    Anticancer Res; 1991; 11(1):97-113. PubMed ID: 2018389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer].
    Zhang T; Li B
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):188-195. PubMed ID: 33819969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tumor development and new therapeutic possibilities].
    Dingermann T
    Med Monatsschr Pharm; 1992 Nov; 15(11):322-32. PubMed ID: 1435496
    [No Abstract]   [Full Text] [Related]  

  • 35. Differential response to retinoic acid of Syrian hamster embryo fibroblasts expressing v-src or v-Ha-ras oncogenes.
    Jetten AM; Barrett JC; Gilmer TM
    Mol Cell Biol; 1986 Oct; 6(10):3341-8. PubMed ID: 3025589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
    Rapp UR; Troppmair J; Beck T; Birrer MJ
    Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of proto-oncogene activation in carcinogenesis.
    Anderson MW; Reynolds SH; You M; Maronpot RM
    Environ Health Perspect; 1992 Nov; 98():13-24. PubMed ID: 1486840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogene expression in human hepatoma cells PLC/PRF/5.
    Motoo Y; Mahmoudi M; Osther K; Bollon AP
    Biochem Biophys Res Commun; 1986 Feb; 135(1):262-8. PubMed ID: 3006683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.
    Manzini C; Venè R; Cossu I; Gualco M; Zupo S; Dono M; Spagnolo F; Queirolo P; Moretta L; Mingari MC; Pietra G
    Oncotarget; 2016 Sep; 7(38):60858-60871. PubMed ID: 27563819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
    Nieborowska-Skórska M; Nakashima M; Ratajczak M; Steplewski Z; Calabretta B; Skórski T
    Folia Histochem Cytobiol; 1994; 32(1):35-40. PubMed ID: 8026602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.